Recently, the National Medical Products Administration (NMPA) has approved the marketing of five innovative drugs, including Anituumab Injection, Sedomingji Injection, Luzunuole Sodium Tablets, Nicalimab Injection, and
As of January–April 2026, compared with the same period in 2025: The number of granted invention patents in China reached 295,178, a year-on-year increase of 10.16%.
This issue selects 8 cutting-edge pharmaceutical achievements: Shanghai Jiao Tong University team discovered new biomarkers for precise identification of Parkinson’s disease and multiple system atrophy; Six
Domestic medical innovation continues to accelerate, the process of technology landing and clinical translation accelerates, and high-quality medical assets are the core targets of capital and
On May 15, 2026, the National Medical Products Administration officially released the “Implementation Measures for the Protection of Drug Trial Data” (hereinafter referred to as the
8 selected pharmaceutical heavyweight achievements in this issue: DNA guided CRISPR reverse regulation of RNA, precise and reversible; Sun Yat sen University reveals that the HNRNPD-GRAMD4
This week, the financing heat in the medical and health field has risen, covering cutting-edge tracks such as CGT upstream reagents, digestive endoscopic surgical robots, ultrasound
Cell and gene therapy (CGT), with its core advantages of precise targeting and significant therapeutic effects, has become the most breakthrough frontier in the global biopharmaceutical
On May 15th, the 12th Shanghai Pujiang Intellectual Property International Forum (2026) and the Yangtze River Delta Pearl River Delta Intellectual Property Cooperation Joint Conference, as
Introduction- Medical and health innovation is accelerating its evolution, cutting-edge technologies continue to break through clinical translation bottlenecks, and high-quality assets are becoming a strategic pivot